Dermatology
| JAK Inhibitors
Dermatology
JAK Inhibitors
Pharmacology of orismilast, a next generation PDE4 inhibitor
book_2
Source:
EADV Congress 2022 - Oral session
calendar_today
Published on Medfyle:
September 2022
import_contacts
5
min
In this medfyle
These preclinical findings demonstrate orismilast is a potent inhibitor of PDE4 subtypes involved in key inflammatory signaling cascades associated with chronic inflammatory diseases.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a highlights summary of an oral session given at the EADV 2022 - 31st Congress and presented by:
Professor Dr. Jonathan Silverberg
George Washington University
Washington, United States
The content is produced by Infomedica, the official reporting partner of EADV 2022.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
